We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Deadlines are approaching for drugmakers to file their CARES Act Amount Information report, detailing the amount of listed drugs and biological products they’ve produced and sold over the year. Read More
The UK is providing booster doses to up to 1 million people every day, while “more than 3 billion people across the world have yet to receive their first dose,” the letter said. Read More
A new consolidated, online clinical trials database that becomes active today in Europe will allow drug sponsors in the EU to run clinical trials in all 27 member states with a single documentation filing. Read More
Michigan’s Attorney General is pursuing court approval to begin an investigation into Eli Lilly over the high insulin prices the company charges. Read More
Prominent industry figures have praised the FDA’s recent draft guidance on using electronic health records (EHRs) and medical claims data in trials, but they hope it will acknowledge issues inherent to real-world data (RWD), offer clarity in certain areas and be flexible as sponsors adjust to the new recommendations. Read More
Researchers from the University of Minnesota and 46brooklyn Research have shown in a new analysis that prices of entecavir, a generic drug that’s one of the first-line treatments used to treat chronic hepatitis B (CHB), from 2014 to 2018 stayed artificially high despite a dramatic increase in generic competition. Read More
Rhode Island’s settlement with the distributors was negotiated separately from a $21 billion global settlement being proposed for other states. Read More
The FDA, as part of its Drug Competition Action Plan, has released final guidance for companies preparing to submit abbreviated new drug applications (ANDAs) to the agency for generic products. Read More